The Nasdaq-listed company said Yuan Sheng Mei Yan will provide channel development services as both sides expand health and wellness offerings and push commercialization in China.
Ping An Biomedical Co., Ltd. said it has signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd., with the two companies aiming for cumulative sales of RMB 500 million within three years. Under the arrangement, Yuan Sheng Mei Yan will act as a channel development service provider, using its health management, wellness services and high-end customer operations capabilities to help expand product channels, broaden market outreach and support terminal service implementation. Ping An Biomedical said it will contribute biotechnology, health products and research and development capabilities, along with product supply and technical support. The company said the partnership is intended to speed commercialization by linking its product pipeline to customer-facing health service scenarios. It expects the deal to help move products from the research and development stage into consumer and service applications, diversify revenue sources and improve market penetration. Yuan Sheng Mei Yan said it has built services in personalized health management, cell-level wellness services and technology-driven anti-aging health services, alongside a user model based on health assessments, customized solutions, dynamic tracking and offline delivery. Ping An Biomedical also highlighted Yuan Sheng Mei Yan’s government-enterprise cooperation and service network development, including partnerships with the government of Huairou District in Beijing and relevant departments in Shenyang. The company said that experience, along with cross-sector ties with medical institutions, wellness organizations and insurance providers, could help extend product use across prevention, care and intervention settings. The release included a safe harbor statement noting that forward-looking statements are subject to risks and uncertainties, including changes in government policy in China, economic conditions, regulation and other factors described in filings with the SEC (U.S. securities regulator).